VIR BIOTECHNOLOGY INC (VIR) Fundamental Analysis & Valuation

NASDAQ:VIR • US92764N1028

Current stock price

9.19 USD
-0.19 (-2.03%)
Last:

This VIR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. VIR Profitability Analysis

1.1 Basic Checks

  • VIR had negative earnings in the past year.
  • VIR had a negative operating cash flow in the past year.
  • In multiple years VIR reported negative net income over the last 5 years.
  • VIR had negative operating cash flow in 4 of the past 5 years.
VIR Yearly Net Income VS EBIT VS OCF VS FCFVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B

1.2 Ratios

  • VIR has a Return On Assets of -43.68%. This is comparable to the rest of the industry: VIR outperforms 54.16% of its industry peers.
  • Looking at the Return On Equity, with a value of -57.23%, VIR is in the better half of the industry, outperforming 60.15% of the companies in the same industry.
Industry RankSector Rank
ROA -43.68%
ROE -57.23%
ROIC N/A
ROA(3y)-37.68%
ROA(5y)-13.52%
ROE(3y)-47.09%
ROE(5y)-15.91%
ROIC(3y)N/A
ROIC(5y)N/A
VIR Yearly ROA, ROE, ROICVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

1.3 Margins

  • VIR has a Gross Margin of 99.96%. This is amongst the best in the industry. VIR outperforms 99.03% of its industry peers.
  • In the last couple of years the Gross Margin of VIR has grown nicely.
  • VIR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.2%
GM growth 5YN/A
VIR Yearly Profit, Operating, Gross MarginsVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. VIR Health Analysis

2.1 Basic Checks

  • VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VIR has more shares outstanding
  • The number of shares outstanding for VIR has been increased compared to 5 years ago.
  • There is no outstanding debt for VIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIR Yearly Shares OutstandingVIR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
VIR Yearly Total Debt VS Total AssetsVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.11, we must say that VIR is in the distress zone and has some risk of bankruptcy.
  • VIR has a Altman-Z score of 1.11. This is in the better half of the industry: VIR outperforms 62.86% of its industry peers.
  • VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.11
ROIC/WACCN/A
WACC8.9%
VIR Yearly LT Debt VS Equity VS FCFVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 5.54 indicates that VIR has no problem at all paying its short term obligations.
  • With a Current ratio value of 5.54, VIR perfoms like the industry average, outperforming 59.19% of the companies in the same industry.
  • VIR has a Quick Ratio of 5.54. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 5.54, VIR is doing good in the industry, outperforming 60.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.54
Quick Ratio 5.54
VIR Yearly Current Assets VS Current LiabilitesVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. VIR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 17.28% over the past year.
  • Looking at the last year, VIR shows a decrease in Revenue. The Revenue has decreased by -7.61% in the last year.
  • VIR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.14% yearly.
EPS 1Y (TTM)17.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.21%
Revenue 1Y (TTM)-7.61%
Revenue growth 3Y-65.12%
Revenue growth 5Y-2.14%
Sales Q2Q%417.78%

3.2 Future

  • VIR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.27% yearly.
  • VIR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.37% yearly.
EPS Next Y13.79%
EPS Next 2Y13.69%
EPS Next 3Y13.89%
EPS Next 5Y12.27%
Revenue Next Year-63.34%
Revenue Next 2Y93.92%
Revenue Next 3Y28.19%
Revenue Next 5Y59.37%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. VIR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VIR. In the last year negative earnings were reported.
  • Also next year VIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIR Price Earnings VS Forward Price EarningsVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIR Per share dataVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • VIR's earnings are expected to grow with 13.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.69%
EPS Next 3Y13.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VIR Dividend Analysis

5.1 Amount

  • VIR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VIR Fundamentals: All Metrics, Ratios and Statistics

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (3/20/2026, 2:24:04 PM)

9.19

-0.19 (-2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23
Earnings (Next)05-05
Inst Owners66.34%
Inst Owner Change6.86%
Ins Owners1.14%
Ins Owner Change1.36%
Market Cap1.47B
Revenue(TTM)68.56M
Net Income(TTM)-437.99M
Analysts82.86
Price Target16.45 (79%)
Short Float %10.56%
Short Ratio3.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.93%
Min EPS beat(2)-35.7%
Max EPS beat(2)37.56%
EPS beat(4)1
Avg EPS beat(4)-2.97%
Min EPS beat(4)-35.7%
Max EPS beat(4)37.56%
EPS beat(8)3
Avg EPS beat(8)-0.36%
EPS beat(12)4
Avg EPS beat(12)-2.24%
EPS beat(16)6
Avg EPS beat(16)-3.78%
Revenue beat(2)1
Avg Revenue beat(2)42.81%
Min Revenue beat(2)-88.02%
Max Revenue beat(2)173.63%
Revenue beat(4)1
Avg Revenue beat(4)-8.82%
Min Revenue beat(4)-88.02%
Max Revenue beat(4)173.63%
Revenue beat(8)3
Avg Revenue beat(8)34.4%
Revenue beat(12)5
Avg Revenue beat(12)14.7%
Revenue beat(16)7
Avg Revenue beat(16)10.63%
PT rev (1m)-3.73%
PT rev (3m)-6.37%
EPS NQ rev (1m)40.87%
EPS NQ rev (3m)41.74%
EPS NY rev (1m)8.03%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)-28.46%
Revenue NQ rev (3m)-28.46%
Revenue NY rev (1m)-15.5%
Revenue NY rev (3m)-24.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.42
P/FCF N/A
P/OCF N/A
P/B 1.92
P/tB 1.98
EV/EBITDA N/A
EPS(TTM)-3.16
EYN/A
EPS(NY)-2.72
Fwd EYN/A
FCF(TTM)-2.48
FCFYN/A
OCF(TTM)-2.45
OCFYN/A
SpS0.43
BVpS4.79
TBVpS4.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.68%
ROE -57.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.96%
FCFM N/A
ROA(3y)-37.68%
ROA(5y)-13.52%
ROE(3y)-47.09%
ROE(5y)-15.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.2%
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.37%
Cap/Sales 7.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.54
Quick Ratio 5.54
Altman-Z 1.11
F-Score4
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)67.48%
Cap/Depr(5y)315.66%
Cap/Sales(3y)13.97%
Cap/Sales(5y)9.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.21%
EPS Next Y13.79%
EPS Next 2Y13.69%
EPS Next 3Y13.89%
EPS Next 5Y12.27%
Revenue 1Y (TTM)-7.61%
Revenue growth 3Y-65.12%
Revenue growth 5Y-2.14%
Sales Q2Q%417.78%
Revenue Next Year-63.34%
Revenue Next 2Y93.92%
Revenue Next 3Y28.19%
Revenue Next 5Y59.37%
EBIT growth 1Y13.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.25%
EBIT Next 3Y9.85%
EBIT Next 5Y10.48%
FCF growth 1Y12.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.23%
OCF growth 3YN/A
OCF growth 5YN/A

VIR BIOTECHNOLOGY INC / VIR Fundamental Analysis FAQ

What is the fundamental rating for VIR stock?

ChartMill assigns a fundamental rating of 3 / 10 to VIR.


What is the valuation status of VIR BIOTECHNOLOGY INC (VIR) stock?

ChartMill assigns a valuation rating of 0 / 10 to VIR BIOTECHNOLOGY INC (VIR). This can be considered as Overvalued.


Can you provide the profitability details for VIR BIOTECHNOLOGY INC?

VIR BIOTECHNOLOGY INC (VIR) has a profitability rating of 2 / 10.


Can you provide the financial health for VIR stock?

The financial health rating of VIR BIOTECHNOLOGY INC (VIR) is 7 / 10.